Service d'Endoscopie Digestive, Hopital Beaujon, Assistance Publqiue des hôpitaux de Paris, Clichy, France.
Department of Gastroenterology, Georges-Pompidou European Hospital, University of Paris-Cité, Paris, Paris, France.
United European Gastroenterol J. 2024 Oct;12(8):1044-1055. doi: 10.1002/ueg2.12552. Epub 2024 Apr 5.
Hepaticogastrostomy drainage through endoscopic ultrasound (EUS-HGS) has emerged in the 2010s as a new technique for biliary decompression in cases of endoscopic retrograde cholangiopancreatography (ERCP) failure for malignant biliary obstruction (MBO). Substantial technical and procedural progress in performing EUS-HGS has been achieved, allowing high technical and clinical success and an acceptable risk of adverse events in studies mainly focusing on short-term outcomes. However, the long-term effects of EUS-HGS and the risk of recurrent biliary obstruction (RBO) have not been fully evaluated.
To evaluate the long-term effects of EUS-HGS and the risk of RBO.
Data from 211 patients undergoing technically successful EUS-HGS in three academic centers were retrospectively collected. Clinical success, adverse events, RBO, and reinterventions were evaluated.
In total, 198 patients underwent technically successful EUS-HGS for MBO. The median overall survival was 144 days [108, 2011] after the procedure. Mean patient age was 69.39 (12.91) years. The cause of MBO was pancreatic cancer (n = 98, 49.5%) followed by cholangiocarcinoma (n = 29, 14.6%). The location of MBO was distal in 27.6% of cases and proximal in 68.4%. Adverse events were observed during the follow-up in 65 patients (33%). On multivariate analysis, the use of partially covered self-expandable metal stents (PCSEMS) was associated with a lower risk of RBO (HR = 0.47 [0.24-0.95], p = 0.034). Additionally, patients with distal stenoses had a trend toward better stent patency (HR = 0.06[0-0.77], p = 0.031). RBO developed in 38 cases (19.1%) mainly due tumor ingrowth (36.8%) with a high success rate of endoscopic management.
While RBO occurred in a notable proportion of patients, the primary cause of mortality was progression of the underlying malignancy rather than stent dysfunction. The efficiency of stents, particularly PCSEMS, and the high success rate of endoscopic management for RBO underscore the effectiveness and reliability of these treatments in managing biliary complications.
经内镜超声引导的肝胆管引流术(EUS-HGS)作为内镜逆行胰胆管造影术(ERCP)失败的恶性胆道梗阻(MBO)患者的胆道减压新技术,于 21 世纪 10 年代出现。在 EUS-HGS 中,技术和程序都取得了实质性的进步,使得在主要关注短期结果的研究中,技术和临床成功率高,不良事件风险可接受。然而,EUS-HGS 的长期效果和复发性胆道梗阻(RBO)的风险尚未得到充分评估。
评估 EUS-HGS 的长期效果和 RBO 的风险。
回顾性收集了三个学术中心 211 例技术成功的 EUS-HGS 患者的数据。评估临床疗效、不良事件、RBO 和再介入。
共有 198 例患者因 MBO 行技术成功的 EUS-HGS。术后中位总生存期为 144 天[108,2011]。患者平均年龄为 69.39(12.91)岁。MBO 的病因依次为胰腺癌(n=98,49.5%)和胆管癌(n=29,14.6%)。MBO 的位置在远端占 27.6%,近端占 68.4%。65 例患者在随访期间出现不良事件(33%)。多变量分析显示,使用部分覆膜自膨式金属支架(PCSEMS)与 RBO 风险降低相关(HR=0.47[0.24-0.95],p=0.034)。此外,远端狭窄患者的支架通畅率有改善趋势(HR=0.06[0-0.77],p=0.031)。38 例(19.1%)患者出现 RBO,主要原因为肿瘤生长(36.8%),内镜治疗成功率高。
尽管相当一部分患者出现 RBO,但死亡的主要原因是基础恶性肿瘤的进展,而不是支架功能障碍。支架(特别是 PCSEMS)的有效性和 RBO 的内镜治疗高成功率,突出了这些治疗方法在管理胆道并发症方面的有效性和可靠性。